Jefferies analyst Faisal Khurshid assumed coverage of Verastem (VSTM) with a Buy rating and a price target of $15, down from $19. The firm sees “a two-pillar story” with drug CO-PACK providing “a valuation floor,” while G12D is “the upside lever” if the company can translate strong China data into “a differentiated, combinable asset.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM:
- Verastem management to meet with Cantor
- Verastem assumed with a Buy at BTIG
- Undervalued Growth Story in Verastem: Strong AVMAPKI FAKZYNJA Launch and Promising KRASG12D Pipeline Drive Buy Rating and $19 Target
- Verastem Earnings Call: Early Momentum, Long Runway Risks
- Verastem: Differentiated Next‑Generation KRAS G12D Inhibitor VS‑7375 Underpins Buy Rating on Compelling Early Clinical Data